The company has not filed an annual or quarterly report since its Q3 FY2022 10-Q, filed Nov 7, 2022. Its latest SEC filing is a 15-12G from Jan 30, 2023.
10-Q for Q3 FY2022, filed Nov 7, 2022
The sections below describe the company as of the FY2021 annual report.
Sells FOTIVDA, a treatment for advanced kidney cancer, to specialty pharmacies and distributors, and develops other cancer drug candidates.
10-K for FY2021, filed Mar 14, 2022We are a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for…View ↗
FOTIVDA became commercially available in the United States on March 22, 2021 and is available to patients through a network of specialty…View ↗
We are also seeking to advance our pipeline of four wholly owned immunoglobulin G1, or IgG1, monoclonal antibody product candidates…View ↗
AVEO sells FOTIVDA to specialty pharmacies and distributors, with product sales counted when the medicine is delivered. Partnerships can bring license and option fees, research funding, milestone payments and royalties on partner product sales.
10-K for FY2021, filed Mar 14, 2022
$42.3M
10-K for FY2021, filed Mar 15, 2022
$42.3M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
FOTIVDA U.S. product revenue, net
Sold outright
10-K for FY2021, filed Mar 14, 2022 |
92% |
FOTIVDA U.S. product revenue, net, FY2021
$38.9M Sources
|
Sold outright |
|
Partnership licensing and royalty revenue
Licensed
|
8.1%
FY2018: 8.5%
|
Partnership licensing and royalty revenue, FY2021
$3.4M Sources
|
Licensed |
AVEO sells FOTIVDA through specialty pharmacies and specialty distributors, which resell it to health care providers and patients.
10-K for FY2021, filed Mar 14, 2022On March 10, 2021, the FDA approved FOTIVDA in the United States for the treatment of adult patients with relapsed or refractory advanced…View ↗
No. It lost $53.3M in FY2021.
10-K for FY2021, filed Mar 15, 2022
−$49.6MView ↗
10-K for FY2021, filed Mar 15, 2022
−$53.3MView ↗
10-K for FY2021, filed Mar 15, 2022
−$57.3MView ↗
10-Q for Q3 FY2022, filed Nov 8, 2022
−$3.3MView ↗
10-Q for Q3 FY2022, filed Nov 7, 2022
Open tableView ↗
8-K, filed Jan 19, 2023
On January 19, 2023, the Company completed its merger with Acacia Acquisition Sub, Inc. (“Merger Sub”), a Delaware corporation and an…View ↗
Grew. Revenue grew 5.6x in 4 years, from $7.6M in FY2017 to $42.3M in FY2021, about 54% a year.
From development to U.S. sales
The older report framed tivozanib as a candidate AVEO was seeking to develop and commercialize in North America; the latest describes FOTIVDA as a marketed U.S. product alongside continued development of tivozanib and other candidates.
10-K for FY2018, filed Mar 14, 2019 10-K for FY2021, filed Mar 14, 2022We are a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs. We are working to…View ↗
Competes with Exelixis, Novartis, Pfizer, BMS, Eisai, NGM Biopharmaceuticals, CatalYm, Daiichi Sankyo, Amgen, Elevation Oncology, Merus, AstraZeneca, Celldex Therapeutics, Sihuan Pharmaceutical Holdings Group, and Roche
10-K for FY2021, filed Mar 14, 2022To date, we believe the key competitors for FOTIVDA in relapsed or refractory advanced RCC include the following FDA-approved treatments…View ↗
Loading...
